Navigation Links
Watson Provides Update on Generic Lidoderm® Application
Date:2/3/2012

PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm® patent challenge, Watson Pharmaceuticals, Inc. (NYSE: WPI) today issued the following statement:

"Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track. We believe questions related to the site where a biostudy supporting the ANDA was conducted have been addressed to FDA's satisfaction.  We continue to work closely with the FDA with the goal of timely approval. Watson has made public comments throughout the year regarding our Lidoderm application, including most recently at our analyst day on January 24th, where the Company restated our confidence that a tentative approval for generic Lidoderm will be received prior to the 30-month stay expiry on July 15, 2012.

"In order not to affect the pending patent litigation trial, it is our policy not to comment during litigation. Therefore, we will not provide additional comment on details that may arise during the trial."

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc., is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to U.S. Food and Drug Administration (FDA) approval of Watson's generic version of Lidoderm, Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with predicting the timing or outcome of product development efforts and FDA  approvals or actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation related to Watson's generic version of Lidoderm; the impact of competitive products and pricing; the timing and success of product launches; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Watson's facilities, products and/or businesses; changes in laws and regulations; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on form 10-K for the year ended December 31, 2010 and its Quarterly Report on Form 10-Q for the period ended September 30, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

All trademarks are the property of their respective owners.(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

 CONTACTS: Investors: 

Patty Eisenhaur  

(862) 261-8141 

  Media: 

Charlie Mayr 

(862) 261-8030


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- , , Marks E-QURE , ... distribution agreement, following similar agreements in Israel and ... 5 billion global market ... a leader in medical devices for the treatment of advanced wound care, announced ... (TeckMedica) in Colombia for the Company,s patented Bio-electrical Signal ...
(Date:1/19/2017)... Md. , Jan. 18, 2017   ... late-stage clinical company developing therapeutics designed to preserve ... of patients, today confirmed plans to initiate a ... Company,s modified-release reformulation of lovastatin lactone designed to ... smithii) in the gut to treat the ...
(Date:1/18/2017)... , Jan. 18, 2017  EnteroMedics Inc. ... medical devices using neuroblocking technology to treat obesity, ... the pricing of an underwritten public offering of ... to deducting underwriting discounts and commissions and offering ... is comprised of Class A Units, priced at ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, a division ... credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing ... recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided ...
(Date:1/19/2017)... ... 2017 , ... Workrite Ergonomics announced this week the launch ... panel system was designed to deliver the ideal blend of acoustic and visual ... the visual privacy required to maintain concentration levels and increase productivity. The tranquility ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top ... Cynthia Murdock and Dr. Shaun Williams have each been chosen by their peers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based ... US market. , Over the past 20 years SFI has been recognized as the ... launched six new clients into the US market. The new clients include: Panacea ...
Breaking Medicine News(10 mins):